Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.64 |
| ▸ | CLK1 | P49759 | 1/20 | 0.64 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.64 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NAT1 | P18440 | 1/20 | 0.57 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.56 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4806036 | 1.00 | CA2 (0.71) | CA2CSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL7558738 | 1.00 | CA2 (0.71) | CA2CSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL14081848 | 0.87 | GSK3B (0.68) | CA2CSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL9245206 | 0.86 | CA2 (0.81) | CA2CSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL4803620 | 0.86 | CA2 (0.73) | CA2CSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL4803625 | 0.86 | CA2 (0.73) | CA2CSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL9245209 | 0.86 | CA2 (0.81) | CA2CSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL19659989 | 0.85 | CA2 (0.71) | CA2CSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL19999122 | 0.85 | CA2 (0.71) | CA2CSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL8310039 | 0.83 | CA2 (1.00) | CA2CSNK2A2CLK1CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002062337-A1 | THIAZOLIDINEDIONES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-15 | — | — | WO | claimed |
| US-7417064-B2 | 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7410982-B2 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410996-B2 | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1567501-B1 | PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060173035-A1 | 3-Aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2006-08-03 | — | — | US | disclosed |
| US-7037932-B2 | Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060058360-A1 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2006-03-16 | — | — | US | disclosed |
| US-20060014779-A1 | 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake | ELI LILLY AND COMPANY (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1397129-B1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1587781-A1 | 3-ARYLOXY/THIO-2,3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1587782-A1 | 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | Eli Lilly and Company (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1567501-A1 | PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2004-09-09 | — | — | US | disclosed |
| WO-2004043904-A1 | 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043903-A1 | 3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043931-A1 | PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1397129-A1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094262-A1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002062337-A1 | THIAZOLIDINEDIONES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014779-A1 | 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake | ADRB3, HTR3C, CHRNB3 | CA2 2036/4885CSNK2A2 758/4885CLK1 3116/4885 |
| US-20060173035-A1 | 3-Aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ADRB3, SLC6A3, SLC6A2 | CA2 2048/4885CSNK2A2 646/4885CLK1 3143/4885 |
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ADRA2C, ADRB1, TPH1 | CA2 2775/4885CSNK2A2 1120/4885CLK1 2367/4885 |
| US-20060058360-A1 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ADRB3, SLC6A2, SLC6A3 | CA2 2790/4885CSNK2A2 762/4885CLK1 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.